




RealRate

PHARMACEUTICAL 2018

Viking Therapeutics Inc
Rank 226 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Viking Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Viking Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 57% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	21,852
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,657
Liabilities, Non-Current	0
Other Assets	270
Other Compr. Net Income	-13
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,507
Other Revenues	0
Property and Equipment	0
Research and Development	13,741
Selling, General and Administrative Expense	5,329

Output Variable	Value in 1000 USD
Assets	22,121
Liabilities	8,657
Expenses	19,070
Revenues	0
Stockholders Equity	13,465
Net Income	-20,578
Comprehensive Net Income	-20,584
BaseVar	25,684
ECR before Limited Liability	57%
Economic Capital Ratio	194%